CLINICAL_TRIALS ClinicalTrials.gov record update

Phase II Trial of Pembrolizumab in Combination With ICE Salvage Chemotherapy for Relapsed/Refractory Hodgkin Lymphoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03077828
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:39:08.308009+00:00
Published At: 2023-06-02T00:00:00+00:00
Record Updated At: 2023-06-02
Results Posted At: 2023-06-02
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Lymphocyte-Rich Classical Hodgkin Lymphoma", "Recurrent Lymphocyte-Depleted Classical Hodgkin Lymphoma", "Recurrent Mixed Cellularity Classical Hodgkin Lymphoma", "Recurrent Nodular Sclerosis Classical Hodgkin Lymphoma", "Refractory Lymphocyte-Depleted Classical Hodgkin Lymphoma", "Refractory Mixed Cellularity Classical Hodgkin Lymphoma", "Refractory Nodular Sclerosis Classical Hodgkin Lymphoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2023-06-02"
protocolSection.identificationModule.nctId: "NCT03077828"
protocolSection.identificationModule.officialTitle: "Phase II Trial of Pembrolizumab in Combination With ICE Salvage Chemotherapy for Relapsed/Refractory Hodgkin Lymphoma"
protocolSection.statusModule.overallStatus: "UNKNOWN"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2023-06-02"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.